Skip to content

Author

J. Zhang

We have 2 of 24 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Oct 2026

Efficacy and safety of camrelizumab plus docetaxel and carboplatin as neoadjuvant therapy for stage II-III triple-negative breast cancer: the HELEN-Trio 011 randomized clinical trial.

The addition of camrelizumab to neoadjuvant docetaxel plus carboplatin significantly increased the pCR rate in patients with stage II-III TNBC, with a manageable safety profile.

D. Jiao, X. Sun, J. Qiao et al. · 0 citations
Review Jul 2026

[Advancement of subtype-based early breast cancer systematic therapy].

Molecular subtype-guided precision medicine now enables individualized systemic therapy for EBC via novel agents and biomarker-driven strategies, optimizing clinical decisions and improving outcomes.

S. Liu, G.-J. Zhang, J. Zhang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.